Among all emerging technologies for cancer therapy, one is both highly accurate and efficient: Antibody-Drug Conjugates (ADCs). These missiles are the first such missiles that allow us to kill cancer cells while doingRead More…
The newer cancer treatment is an antibody-drug conjugate (ADC) that combines the immunoprecision of monoclonal antibodies with the cytotoxicity of chemotherapy. It’s a two-step mechanism to ensure therapeutic molecules get to the cancerRead More…
The highly anticipated 115th American Association for Cancer Research (AACR 2024) Annual Meeting opened in San Diego, USA. As the focus of the cancer research community, scientists, clinicians, and cancer researchers fromRead More…
Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…
An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…